Editor’s Message and Issue Highlights—March–April 2015

In this study, the authors specifically examined IA among subjects with obsessive-compulsive disorder (OCD). All enrolled patients with OCD alone (n=27) and OCD and IA (n=11) were treated for OCD for a period of one year. At 12 months, only two of the 11 patients with OCD and IA continued to meet the criteria for IA, and the authors concluded that treatment of the underlying disorder, in this case OCD, improved IA, supporting their hypothesis that IA is a symptom of an underlying disorder and not a primary disorder itself. The authors state several limitations to their study that might impact their conclusions and acknowledge that more carefully controlled studies are needed to resolve the diagnostic controversies surrounding IA. Next, Kolikonda et al present a case report titled, “Atypical Myopathy: Pentazocine Induced,” which describes a case of atypical myopathy that included wasting of musculature in the gluteal region bilaterally and stiffness and woody induration in the legs of a 42-year-old man as a result of one and a half years of intramuscular injections of pentazocine. Though its use, particularly in intramuscular form, is rare in this country, pentazocine may still be used in areas less medically advantaged, and clinicians should be alerted to this potential side effect and avoid repeated administration of intramuscular pentazocine. Following this, Wadekar et al present this month’s installment of “Hot Topics in Neuroscience.” In their article, “Patien...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Editor's Message: Issue Highlights Amir H. Kalali drug development ICNS Innovations in Clinical Neuroscience ISCTM neurology psychiatry Source Type: research